摘要
目的探讨检测血清肿瘤标志物癌抗原19-9(CA19-9)在胰腺癌诊断和预后中的作用。方法回顾性分析了105例胰腺癌患者、70例非胰腺外分泌恶性肿瘤患者以及30例胰腺良性疾病患者术前血清CA19-9的水平。结果血清CA19-9在胰腺癌患者中的表达水平显著高于胰岛细胞瘤、壶腹癌以及良性胰腺疾病患者(P<0.05),而与肝外胆管癌患者的CA19-9水平无显著差异(P>0.05)。CA19-9对胰腺癌诊断的敏感性和特异性分别为80%和43%。CA19-9在胰体尾癌患者中的表达水平显著高于胰头癌患者(P>0.05)。CA19-9不受肿瘤大小以及可切除性的影响(P>0.05),但在Ⅳ期胰腺癌患者中明显提高(P<0.05)。结论CA19-9对胰腺癌的诊断具有一定的作用,但特异性不高,高水平的CA19-9提示病期较晚,预后不良。
Objective Serum tumor marker carbohydrate antigen 19 -9 （CA19 -9） was investigated to evaluate the values for the diagnosis and prognosis of pancreatic cancer. Methods Preoperative serum CA19 -9 was measured in 105 pancreatic cancer, 70 non - pancreatic malignance, and 30 benign panereatie diseases. Results The level of CA19 - 9 in pancreatic cancer was markedly higher than that of islet cell carcinoma, ampulla of rater carcinoma, and benign pancreatic diseases （ P 〈0. 05 ）, but was no significant difference with that of extrahepatic cholangiocarcinomas （ P 〉0.05）. The sensitivity and specificity of CA19 -9 for the pancreatic cancer were 80% and 43% respectively. The level of CA19 -9 in pancreatic cancer of head was higher than that of pancreatic cancer of body and tail. There was no significant relationship with the tumor size and resectabillty （ P 〉 0.05） , but the level of CA19 -9 was increased obviously （ P 〈 0.05 ）. Conclusion Serum CA19 -9 has a significant role for pancreatic cancer diagnosis, but the specificity is low. High level of CA19 -9provides the clue for advanced stage and poor prognosis.
出处
《临床和实验医学杂志》
2008年第5期14-15,共2页
Journal of Clinical and Experimental Medicine
基金
国家自然科学基金资助(NO30500582)
